Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions.

Authors

J Mark Albrecht
Benjamin R Cooper
Jacquelyn D Waller
Colby L. Presley MD, Lehigh Valley Health NetworkFollow
Kayd J Pulsipher
Chandler W Rundle
Robert P Dellavalle

Publication/Presentation Date

2-15-2023

Abstract

Nirmatrelvir-ritonivir (Paxlovid) recently received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19). Literature has linked numerous cutaneous adverse effects to nirmatrelvir and ritonavir, the copackaged tablets within Paxlovid. A review and comparison of these adverse effects to the common cutaneous manifestations of COVID-19 is provided. Numerous drug-to-drug interactions exist between nirmatrelvir-ritonivir and commonly-used medications within dermatology.

Volume

29

Issue

1

ISSN

1087-2108

Published In/Presented At

Albrecht, J. M., Cooper, B. R., Waller, J. D., Presley, C. L., Pulsipher, K. J., Rundle, C. W., & Dellavalle, R. P. (2023). Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions. Dermatology online journal, 29(1), 10.5070/D329160209. https://doi.org/10.5070/D329160209

Disciplines

Medicine and Health Sciences

PubMedID

37040906

Department(s)

Department of Medicine, Department of Medicine Fellows and Residents, Fellows and Residents

Document Type

Article